Special Issue "Epigenetics and Disease - 2021"

A special issue of Diseases (ISSN 2079-9721).

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Dr. Mark Brown
E-Mail Website
Guest Editor
1. Education Section, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
2. Institute for Learning and Teaching, Colorado State University, Fort Collins, CO 80523, USA
3. Department of Ethnic Studies, Colorado State University, Fort Collins, CO 80523, USA
4. Epidemiology Section, Colorado School of Public Health, Fort Collins, CO 80523, USA
5. Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA
Special Issues and Collections in MDPI journals

Special Issue Information

Dear colleagues,

This Special Issue builds from the 2020 issue on the topic of “Epigenetics and Disease.” Epigenetic mechanisms regulate the broad synchronization in patterns of gene expression that ultimately dictate cellular consequences. Aberrations in these epigenetic mechanisms are known to be associated with a range of diseases. This correlation between epigenetic aberrations and disease is the continued focus of this 2021 Special Issue of Diseases. For this issue, we invite papers related to the molecular, cellular, and clinical significance of epigenetic aberrations as well as treatments based on the modulation of epigenetic mechanisms in the clinical management of disease.

Dr. Mark Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • molecular genetics
  • molecular basis of disease
  • chromatin modifications

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Editorial
Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic
Diseases 2021, 9(1), 12; https://0-doi-org.brum.beds.ac.uk/10.3390/diseases9010012 - 01 Feb 2021
Viewed by 685
Abstract
With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it [...] Read more.
With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it is that, in a world of evolving zoonotic viruses, we must be better prepared for the next deadly outbreak. While the acute nature of the COVID-19 pandemic demanded a highly specific approach, it is advisable to consider the breadth of seemingly endless possibilities in our approach to managing the next inevitable occurrence of an outbreak. Though there is little chance of discovering a “magic pill” to combat all future pathogens, the highly conserved nature of non-surface viral proteins exposes an “Achilles’ heel” in the structural genome of viral pathogens. Herein, we consider the potential of targeting such proteins to develop broad-spectrum therapeutics for the future. To illustrate this point, we outline the therapeutic potential of targeting the nonstructural protein 16 methyltransferase, which is conserved across most coronaviruses. Full article
(This article belongs to the Special Issue Epigenetics and Disease - 2021)
Show Figures

Figure 1

Back to TopTop